Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges

Devaraj Ezhilarasan; Thangavelu Lakshmi; Sreekanth Kumar Mallineni

doi:10.2217/nnm-2021-0364

Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges

Devaraj Ezhilarasan
, Thangavelu Lakshmi
, Sreekanth Kumar Mallineni

Saveetha Institute of Medical and Technical Sciences (Deemed to be University)
Majmaah University

Research output: Contribution to journal › Review article › peer-review

58 Scopus citations

Abstract

Most anticancer drugs often fail in clinical trials due to poor solubility, poor bioavailability, lack of targeted delivery and several off-target effects. Polymeric nanoparticles such as poly(lactide), poly(lactic-co-glycolic acid), ALB-loading paclitaxel (Abraxane® ABI-007), lomustine-loaded chitosan, gelatin (decorated with EGF receptor-targeted biotinylated EGF) and so on offer controlled and sustained drug-release properties, biocompatibility and promising anticancer effects. EGF, folic acid, transferrin, sigma and urokinase plasminogen activator receptors-targeting nano preparations improve bioavailability and accumulate drugs on the lung tumor cell surface. However, route of administration, size, pharmacokinetic properties, immune clearance and so on hamper nanomedicines' clinical uses. This review focuses on the benefits, avenues and challenges of nanoparticle-based drug-delivery systems for lung cancer treatment.

Original language	English
Pages (from-to)	1855-1869
Number of pages	15
Journal	Nanomedicine
Volume	17
Issue number	24
DOIs	https://doi.org/10.2217/nnm-2021-0364
State	Published - 1 Oct 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

doxorubicin
liposomes
lung cancer
paclitaxel
polymeric nanoparticles

Access to Document

10.2217/nnm-2021-0364

Cite this

@article{f53d73a2082442fc9e28137fa75d04bd,

title = "Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges",

abstract = "Most anticancer drugs often fail in clinical trials due to poor solubility, poor bioavailability, lack of targeted delivery and several off-target effects. Polymeric nanoparticles such as poly(lactide), poly(lactic-co-glycolic acid), ALB-loading paclitaxel (Abraxane{\textregistered} ABI-007), lomustine-loaded chitosan, gelatin (decorated with EGF receptor-targeted biotinylated EGF) and so on offer controlled and sustained drug-release properties, biocompatibility and promising anticancer effects. EGF, folic acid, transferrin, sigma and urokinase plasminogen activator receptors-targeting nano preparations improve bioavailability and accumulate drugs on the lung tumor cell surface. However, route of administration, size, pharmacokinetic properties, immune clearance and so on hamper nanomedicines' clinical uses. This review focuses on the benefits, avenues and challenges of nanoparticle-based drug-delivery systems for lung cancer treatment.",

keywords = "doxorubicin, liposomes, lung cancer, paclitaxel, polymeric nanoparticles",

author = "Devaraj Ezhilarasan and Thangavelu Lakshmi and Mallineni, \{Sreekanth Kumar\}",

note = "Publisher Copyright: {\textcopyright} 2022 Future Medicine Ltd.",

year = "2022",

month = oct,

day = "1",

doi = "10.2217/nnm-2021-0364",

language = "English",

volume = "17",

pages = "1855--1869",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Taylor and Francis Ltd.",

number = "24",

}

TY - JOUR

T1 - Nano-based targeted drug delivery for lung cancer

T2 - therapeutic avenues and challenges

AU - Ezhilarasan, Devaraj

AU - Lakshmi, Thangavelu

AU - Mallineni, Sreekanth Kumar

PY - 2022/10/1

Y1 - 2022/10/1

N2 - Most anticancer drugs often fail in clinical trials due to poor solubility, poor bioavailability, lack of targeted delivery and several off-target effects. Polymeric nanoparticles such as poly(lactide), poly(lactic-co-glycolic acid), ALB-loading paclitaxel (Abraxane® ABI-007), lomustine-loaded chitosan, gelatin (decorated with EGF receptor-targeted biotinylated EGF) and so on offer controlled and sustained drug-release properties, biocompatibility and promising anticancer effects. EGF, folic acid, transferrin, sigma and urokinase plasminogen activator receptors-targeting nano preparations improve bioavailability and accumulate drugs on the lung tumor cell surface. However, route of administration, size, pharmacokinetic properties, immune clearance and so on hamper nanomedicines' clinical uses. This review focuses on the benefits, avenues and challenges of nanoparticle-based drug-delivery systems for lung cancer treatment.

AB - Most anticancer drugs often fail in clinical trials due to poor solubility, poor bioavailability, lack of targeted delivery and several off-target effects. Polymeric nanoparticles such as poly(lactide), poly(lactic-co-glycolic acid), ALB-loading paclitaxel (Abraxane® ABI-007), lomustine-loaded chitosan, gelatin (decorated with EGF receptor-targeted biotinylated EGF) and so on offer controlled and sustained drug-release properties, biocompatibility and promising anticancer effects. EGF, folic acid, transferrin, sigma and urokinase plasminogen activator receptors-targeting nano preparations improve bioavailability and accumulate drugs on the lung tumor cell surface. However, route of administration, size, pharmacokinetic properties, immune clearance and so on hamper nanomedicines' clinical uses. This review focuses on the benefits, avenues and challenges of nanoparticle-based drug-delivery systems for lung cancer treatment.

KW - doxorubicin

KW - liposomes

KW - lung cancer

KW - paclitaxel

KW - polymeric nanoparticles

UR - https://www.scopus.com/pages/publications/85132345230

U2 - 10.2217/nnm-2021-0364

DO - 10.2217/nnm-2021-0364

M3 - Review article

C2 - 35311343

AN - SCOPUS:85132345230

SN - 1743-5889

VL - 17

SP - 1855

EP - 1869

JO - Nanomedicine

JF - Nanomedicine

IS - 24

ER -

Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this